KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 resultsBijal Shah, William G. Wierda, Michael R. Bishop et al.|Blood|2021Cited by 204
Initial results from a phase II study of dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (DA-EPOCH) ± rituximab (R) + tafasitamab (tafa) for adults with newly-diagnosed (ND) Philadelphia chromosome negative (Ph-) B lymphoblastic leukemia (B-ALL).Noam E. Kopmar, Ryan D. Cassaday, Jonathan R. Fromm et al.|Journal of Clinical Oncology|2025Cited by 0
Phase II study of dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (DA-EPOCH) ± rituximab (R) + tafasitamab (tafa) in adults with newly diagnosed (ND) Philadelphia chromosome–negative (Ph-) B lymphoblastic leukemia (B-ALL).Noam E. Kopmar, Ryan D. Cassaday, Erik L. Kimble et al.|Journal of Clinical Oncology|2026Cited by 0
Randomized phase 2 trial of CPX-351 vs. CLAG-M (cladribine, cytarabine, G-CSF, and mitoxantrone) for medically unfit adults with acute myeloid leukemia or other high-grade myeloid neoplasmsAnna B. Halpern, Roland B. Walter, Megan Othus et al.|Leukemia|2026Cited by 0